Pulmonary Edema News and Research

RSS

Vesicular stomatitis virus-based COVID vaccines demonstrate potent antiviral efficacy against SARS-CoV-2 variants

Scientists from the National Institutes of Health, USA, have recently demonstrated the immunogenicity and protective efficacy of two vesicular stomatitis virus (VSV)-based coronavirus disease 2019 (COVID-19) vaccines in hamsters.

6 Sep 2021

Review details clinical signs of SARS-CoV-2 infection in domestic and wild cats

Now, a new systematic review has been published in the journal Animals that focuses on the clinical symptoms in felines diagnosed with SARS-CoV-2 worldwide.

13 Jul 2021

Local anesthetic procaine inhibits SARS-CoV-2 in vitro

Research has shown that procaine and procaine-hydrochloride can reduce replication of SARS-CoV-2 and influenza A viruses in infected cells and reduce the production of cytokines by the viruses, making them potentially useful for treating COVID-19.

10 Jun 2021

Ultrasound examinations can be deployed to detect and treat lung congestion in hemodialysis patients

Accumulation of water in the lungs (lungcongestion) is a common condition in hemodialysis patients, particularly in those at high cardiovascular risk, like those presenting coronary artery disease and/or heart failure.

7 Jun 2021

Is COVID-19 a new disease?

In a review recently published in The Lancet Respiratory Medicine journal by Osuchowski et al. (May 6th, 2021) the currently known pathophysiology of COVID-19 is laid out to describe the mechanistic features that make COVID-19 distinct from many conditions previously thought to be similar.

9 May 2021

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of SARS-CoV-2 emerging, the COVID-19 pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study reviews the potential for curcumin, a natural alkaloid derived from turmeric, and nanosystems to treat COVID-19.

16 Apr 2021

Experimental evidence that ADAM17 inhibition prevents severe COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus that is contagious in humans. It is the causal agent of the ongoing coronavirus 2019 (COVID-19) pandemic. This virus causes a mild to severe infection and has claimed over 2.95 million lives worldwide. SARS-CoV-2 is the successor to SARS-CoV-1, the virus that caused the 2002–2004 SARS outbreak.

13 Apr 2021

Kruppel-like factor 2 may be a major determinant of acute respiratory distress syndrome in COVID-19 patients

A study conducted at the University of Chicago, USA, has recently revealed that downregulation of an endothelial transcription factor, Kruppel-like factor 2, by SARS-CoV-2 is responsible for ARDS frequently observed in critically ill COVID-19 patients.

19 Jan 2021

High altitude experts explain pneumolysis caused by COVID-19

The current COVID-19 pandemic has caused over 1 million deaths which can be attributed to its severe progressive pulmonary compromise.

21 Dec 2020

Drugs targeting neutrophils could reduce ARDS in severe COVID-19

Scientists in Taiwan recently published a report on their use of anti-neutrophil strategies to treat acute respiratory distress syndrome (ARDS) – a life-threatening condition that can arise in critical COVID-19 cases – in the journal Frontiers in Pediatrics.

15 Nov 2020

Adult stem cell-based lung organoid models emulate host immune response in fatal COVID-19

Recently, a team of researchers from the University of California San Diego and The Scripps Research Institute, CA, USA, showed that an integrated stem cell-based disease modeling and computational approach is crucial for simulating the host immune response in fatal COVID-19 patients.

19 Oct 2020

New technique uses ultrasound to provide non-invasive assessments of lung health

Researchers from North Carolina State University and the University of North Carolina have developed a technique that uses ultrasound to provide non-invasive assessments of pulmonary fibrosis and pulmonary edema.

15 Oct 2020

Serum protein shows therapeutic value against severe COVID-19-like features in mouse model

A new study published on the preprint server bioRxiv* in August 2020 reports the disease-mitigating effects of a serum protein called serum amyloid P (SAP) in mice exposed to a peptide that mimics the clinical signs of severe COVID-19 in humans.

30 Aug 2020

COVID-19 patients with hypoxia respond positively to a treatment, study shows

Covid-19 patients with hypoxia respond positively to icatibant treatment, Radboud university medical center researchers wrote in JAMA Network Open.

19 Aug 2020

Novel strategy provides new hope to fight COVID-19

A novel strategy has been developed by Novateur Ventures, which provides new hope in battle against COVID-19. The study titled 'A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes' was published in Frontiers in Pharmacology, a leading peer-reviewed journal.

12 Aug 2020

Certain antibodies may cause the dangerous part of COVID-19 disease

A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.

15 Jul 2020

New study explores post-COVID-19 inflammatory condition in children

In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association with prior exposure or infection to SARS-CoV-2.

25 Jun 2020

First independent test of proposed subphenotypes of COVID-19-related ARDS

In a new paper published online in the Annals of the American Thoracic Society, researchers have been unable to produce two theorized subphenotypes of COVID-19 related acute respiratory distress syndrome (ARDS).

27 May 2020

Equating COVID-19 with high altitude pulmonary edema can have dangerous implications

Early reports of COVID-19 symptoms and the compelling need to quickly identify treatment options and curb the growing number of critically ill patients have led to erroneous and potentially dangerous comparisons between COVID-19 and other respiratory diseases like high altitude pulmonary edema, or HAPE.

30 Apr 2020

How toxic are chloroquine and hydroxychloroquine to cells?

The spread of the pandemic disease COVID-19 caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has now reached almost every country of the world, with over 3.11 million cases and over 217,000 deaths as of April 29, 2020.

29 Apr 2020